Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye scans may foretell diabetes vision loss and heart trouble

NCT ID NCT07417410

Knowledge-focused Sponsor: Association for Innovation and Biomedical Research on Light and Image Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This observational study will follow 1,000 people with type 2 diabetes for one year to see if changes in the eye's blood vessels and tissues can predict worsening diabetic retinopathy and related heart problems. Researchers will use advanced imaging and medical records to track eye health and major cardiovascular events like heart attack or stroke. The goal is to better identify who is at risk, so doctors can intervene earlier.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors identify which patients with diabetes are at highest risk for vision loss or heart problems, allowing earlier and more personalized care.
What could go wrong
This is an observational study, not a treatment trial. It may find patterns that are not strong enough to reliably predict outcomes, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

1.000 participants with T2D will be included in this study, in a recruitment period of 12 months.

Ages

35 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed with type 2 diabetes according to the 1985 WHO criteria. * Age between 35 and 90 years. * Retrospective visit or referenced patients. For the retrospective visit, a documented follow-up of 1-5 years is required, with at least one clinical visit. For the referenced patients, it is required that they have either diabetic retinopathy at the baseline visit, the presence of at least one cardiovascular risk factor at the baseline visit, or cardiovascular complications at the baseline visit. * Signed informed consent. Exclusion Criteria: * Previous laser photocoagulation or intravitreal injections (consider if corticosteroids were administered). * Presence of clinically significant macular edema (CSME) with vision loss or requiring immediate treatment. * Proliferative diabetic retinopathy. * Any ocular surgery within the previous 3 months. * Renal Replacement Therapy (Hemodialysis, Peritoneal Dialysis). * Severe systemic illness, subject to investigator's judgment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic retinopathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetic retinopathy type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetic retinopathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AIBILI-Clinical Trial Centre

    RECRUITING

    Portugal, Coimbra District, 3000-548, Portugal

More trials for these conditions

Other studies related to the condition(s) this trial covers.